News and updates
The root of evil: pre-leukemic clones that survive chemotherapy are linked to a ...
Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission.
Stopping tyrosine kinase inhibitors in a very large cohort of European chronic ...
Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.
Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinica...
Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome
Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab
Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will...
Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treate...
Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes
A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT...
A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!
EHA Award winners put in the spotlight in Copenhagen
Copenhagen, June 9 2016. At the 21st Congress of the European Hematology Association (EHA) in Copenhagen, in total thirteen hematology researchers will be awarded for their work. Research is the engine that drives improvements in patient care which is why EHA is keen in investing in Awards and Grants to stimulate and support hematology research.
PRESS RELEASE: The future of research in hematology is here
The Hague, January 27, 2016 In the February 2016 issue of Haematologica, critical research of blood and blood-forming organs in Europe is given a boost. The European Hematology Association Roadmap for European Hematology Research: A Consensus Document summarizes the current status of basic, translational and clinical hematology research and identifies areas of unmet scientific and medical need in Europe. It provides guidance for European and national policy makers, funding agencies, charities, research institutes and researchers when they make decisions on initiating or funding research and developing research programs.
A European Reference Network for Rare Hematological Diseases
You may have heard of European Reference Networks (ERNs). But most likely you have not because they do not exist yet. ERNs are networks of specialized hospital departments and research centers to treat rare or low-prevalent complex diseases and they are foreseen to be established by the end of this year. EHA wants to support the establishment of an ERN for Rare Hematological Diseases.
Survey Monitoring H2020 – your input is needed!
We need your input to improve Horizon 2020 and the next Research and Innovation Framework Programme of the European Union.
IMI2 Call for Research Proposals
On October 6, 2015, the Innovative Medicines Initiative (IMI) launched its 6th Call for proposals under IMI 2. This call includes, under the program “Big Data for Better Outcomes programme”, the topic:
Development of an outcomes-focused platform to empower policy makers and clinicians to optimize care for patients with hematologic malignancies.
A new targeted combination therapy with potential to eliminate relapsed chronic ...
Vienna, June 12, 2015 – Promising results from an early phase trial combining the anti-bcl-2 drug Venetoclax with Rituximab to eliminate CLL are presented by Dr Andrew Roberts.
Treatment and survival of patients with chronic myeloid leukemia (CML) in Europe
Vienna, June 12, 2015 – On behalf of the EUTOS network, Dr Hoffmann will present data of a web-based registry of newly diagnosed CML patients.
Adding elotuzumab to standard treatment for multiple myeloma significantly reduc...
Vienna, June 12, 2015 – On behalf of the ELOQUENT-2 investigators, Dr Dimopoulos will present the positive results on Elotuzumab with Lenalidomide from a phase III study in patients with multiple myeloma.
Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresis...
Vienna, June 12, 2015 –Dr Guryanova will present a new mechanism for chemoresistance in AML based on acquired DNA mutations.